Oppenheimer & Co. Inc. Increases Stock Holdings in Novartis AG (NYSE:NVS)

Oppenheimer & Co. Inc. boosted its stake in shares of Novartis AG (NYSE:NVSFree Report) by 1.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 30,996 shares of the company’s stock after buying an additional 537 shares during the period. Oppenheimer & Co. Inc.’s holdings in Novartis were worth $3,130,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Frazier Financial Advisors LLC purchased a new stake in shares of Novartis in the fourth quarter valued at $26,000. Operose Advisors LLC purchased a new stake in Novartis in the 3rd quarter worth about $28,000. Planned Solutions Inc. purchased a new stake in Novartis in the 4th quarter worth about $31,000. AdvisorNet Financial Inc lifted its stake in Novartis by 480.0% in the fourth quarter. AdvisorNet Financial Inc now owns 348 shares of the company’s stock worth $35,000 after purchasing an additional 288 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Novartis during the third quarter valued at approximately $39,000. 13.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on NVS shares. The Goldman Sachs Group initiated coverage on Novartis in a research note on Thursday, May 30th. They set a “buy” rating and a $120.00 price target for the company. BMO Capital Markets boosted their target price on shares of Novartis from $114.00 to $116.00 and gave the company a “market perform” rating in a research note on Wednesday, April 24th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $116.67.

Get Our Latest Research Report on Novartis

Novartis Stock Down 0.8 %

Shares of NYSE:NVS opened at $105.32 on Friday. The business’s 50 day moving average is $98.84 and its 200 day moving average is $100.30. The stock has a market cap of $215.27 billion, a P/E ratio of 14.21, a price-to-earnings-growth ratio of 1.63 and a beta of 0.58. Novartis AG has a 52-week low of $92.19 and a 52-week high of $108.78. The company has a quick ratio of 0.71, a current ratio of 0.90 and a debt-to-equity ratio of 0.43.

Novartis (NYSE:NVSGet Free Report) last announced its quarterly earnings results on Tuesday, April 23rd. The company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.73 by $0.07. Novartis had a return on equity of 32.15% and a net margin of 31.33%. The firm had revenue of $11.83 billion for the quarter, compared to analyst estimates of $11.50 billion. Sell-side analysts predict that Novartis AG will post 7.27 EPS for the current year.

Novartis Company Profile

(Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Featured Stories

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.